Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO
Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies,…
09 Oct 2026
Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Roche has notched a twelfth indication on the belt of its blockbuster cancer therapy Tecentriq (atezolizumab), following the US Food and Drug Administration’s (FDA) decision to approve the drug in…
09 Oct 2026
Bio-Techne opens GMP small molecule facility in Bristol, UK
Life science tools and diagnostics provider Bio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to good manufacturing practice (GMP) grade small molecules. The purpose-built 10,000ft² site…
09 Oct 2026
Biohaven partners with Ono in $100m IgG degrader deal
Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan immunoglobulin G (IgG) degrader portfolio. The transaction grants…
08 Oct 2026
Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies – allowing the company to enter a market attracting growing attention…
08 Oct 2026
Change lifestyle before giving children weight loss medication, WHO says
The World Health Organization (WHO) has urged health authorities to first seek lifestyle interventions to treat obesity in children and adolescents rather than opting for pharmacological treatment. In its first…
08 Oct 2026
FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer. This regimen is indicated for adults…